FP
SUPN icon

Foundry Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Foundry Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-17,597
Closed -$469K – 379
2021
Q3 		$469K Sell
17,597
-168,308
-91% -$4.52M 0.02% 291
2021
Q2 		$5.72M Sell
185,905
-4,725
-2% -$145K 0.2% 158
2021
Q1 		$4.99M Buy
+190,630
New +$5.33M 0.16% 191

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Foundry Partners's SUPN Position: Q4 2021 in Review

Foundry Partners sold out of Supernus Pharmaceuticals (SUPN) in Q4 2021, closing a stake of 17,597 shares — an estimated $469K sold.

Foundry Partners first reported a position in SUPN in Q1 2021 and held it in 3 quarters. The position peaked at $5.72M in Q2 2021. 235 funds tracked by Wall St. Rank hold SUPN as of Q4 2021.

  • Foundry Partners reported no remaining Supernus Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Foundry Partners sold 17,597 Supernus Pharmaceuticals shares in Q4 2021, an estimated $469K.
  • Foundry Partners first reported a position in Supernus Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • Foundry Partners's Supernus Pharmaceuticals position peaked at $5.72M in Q2 2021.
  • 235 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2021.

Based on Foundry Partners's 13F filing for Q4 2021, filed 26 Jan 2022.